F0AT1 (SLC6A19) inhibitor ameliorates the lipotoxicity and dyslipidemia to induce endogenous fibroblast growth factor 21 (FGF21) to treat fatty liver associated diseases [33]. This evidence concerns the gene FGF21 and metabolic syndrome.